GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuCell Corp (NAS:ICCC) » Definitions » Cyclically Adjusted Price-to-FCF

ImmuCell (ImmuCell) Cyclically Adjusted Price-to-FCF : (As of Apr. 28, 2024)


View and export this data going back to 1995. Start your Free Trial

What is ImmuCell Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


ImmuCell Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for ImmuCell's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuCell Cyclically Adjusted Price-to-FCF Chart

ImmuCell Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ImmuCell Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ImmuCell's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, ImmuCell's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmuCell's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuCell's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ImmuCell's Cyclically Adjusted Price-to-FCF falls into.



ImmuCell Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

ImmuCell's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, ImmuCell's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.104/129.4194*129.4194
=-0.104

Current CPI (Dec. 2023) = 129.4194.

ImmuCell Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 0.086 99.695 0.112
201406 -0.080 100.560 -0.103
201409 -0.156 100.428 -0.201
201412 -0.252 99.070 -0.329
201503 0.132 99.621 0.171
201506 -0.105 100.684 -0.135
201509 0.067 100.392 0.086
201512 -0.037 99.792 -0.048
201603 -0.101 100.470 -0.130
201606 -0.030 101.688 -0.038
201609 -0.260 101.861 -0.330
201612 -0.450 101.863 -0.572
201703 -0.745 102.862 -0.937
201706 -0.792 103.349 -0.992
201709 -0.945 104.136 -1.174
201712 -0.852 104.011 -1.060
201803 -0.176 105.290 -0.216
201806 -0.088 106.317 -0.107
201809 -0.132 106.507 -0.160
201812 -0.043 105.998 -0.053
201903 0.085 107.251 0.103
201906 -0.061 108.070 -0.073
201909 -0.065 108.329 -0.078
201912 -0.102 108.420 -0.122
202003 -0.055 108.902 -0.065
202006 -0.013 108.767 -0.015
202009 -0.297 109.815 -0.350
202012 -0.018 109.897 -0.021
202103 -0.135 111.754 -0.156
202106 -0.019 114.631 -0.021
202109 -0.053 115.734 -0.059
202112 -0.015 117.630 -0.017
202203 -0.022 121.301 -0.023
202206 -0.074 125.017 -0.077
202209 -0.257 125.227 -0.266
202212 -0.360 125.222 -0.372
202303 -0.445 127.348 -0.452
202306 -0.179 128.729 -0.180
202309 -0.120 129.860 -0.120
202312 -0.104 129.419 -0.104

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ImmuCell  (NAS:ICCC) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


ImmuCell Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of ImmuCell's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmuCell (ImmuCell) Business Description

Industry
Traded in Other Exchanges
Address
56 Evergreen Drive, Portland, ME, USA, 04103
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. It has two segments Scours and Mastitis. The company generates the majority of its revenue from the United States.
Executives
Bryan K. Gathagan director 56 EVERGREEN DRIVE, PORTLAND ME 04103
David Cunningham director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Gloria F Basse director 56 EVERGREEN DRIVE, PORTLAND ME 04103
David Scott Tomsche director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Steven T. Rosgen director C/O IMMUCELL CORPORATION, 56 EVERGREEN DR., PORTLAND ME 04103
Norman H Pessin other: See Explanation of Responses C/O LEVY, HARKINS & CO., INC., 366 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Brian L. Pessin other: See Explanation of Responses 310 EAST 75TH STREET, APT. 2A, NEW YORK NY 10021
Joseph H Crabb director, officer: Vice President and CSO IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Elizabeth Luttrell Williams officer: Vice Pres. of Mfg Operations C/O IMMUCELL CORPORATION, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Jonathan E Rothschild director, 10 percent owner C/O IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Linda Rhodes director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Paul R Wainman director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Michael F Brigham director, officer: President and CEO IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Bobbi Jo Kunde other: Director of Sales and Marketin 56 EVERGREEN DRIVE, PORTLAND ME 04103
Robert C Bruce director 56 EVERGREEN DRIVE, PORTLAND ME 04103